ArticleEuropean journal of pain (London, England)2025
A Significant Decline in the Number of Newly Dispensed Analgesics During the First COVID-19 Lockdown in The Netherlands.
Article in European journal of pain (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross-sectional study.Clinical pharmacology and therapeutics · 2026Article
- A Significant Decline in the Number of Newly Dispensed Analgesics During the First COVID-19 Lockdown in The Netherlands.European journal of pain (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic disrupted healthcare systems worldwide, including the postponement of non-urgent care and reallocation of resources toward COVID-19 patients. The aim of this study was to assess the impact of the first Dutch COVID-19 lockdown on the initiation of new analgesic prescriptions.
methodsThis study analysed dispensing data from 1890 Dutch pharmacies, covering approximately 96% of the population (5.46 million patients). The number of first-time prescription analgesics dispensed (ATC2 N02 class, e.g., opioids, anilides) was compared between the first halves of 2019 and 2020. First-time users were defined as patients who had not received the drug in the preceding year. Data were stratified by age group (children, adolescents, adults, elderly), sex and time periods: weeks 1-11 (pre-lockdown 2020), 12-19 (lockdown) and 20-26 (post-lockdown).
resultsThe total number of first-time dispensed analgesic drugs was significantly lower in 2020 (367,094) than in 2019 (388,973, p = 0.021), with a notable reduction occurring during the lockdown period (p = 0.003). Significant declines in first-time dispensed analgesic drugs were observed among adolescents and adults during lockdown (p < 0.001), particularly among females. In contrast, no significant changes were found among children and the elderly. The number of first-time dispensed analgesic drugs during the pre- and post-lockdown periods was comparable between the 2 years.
conclusionDelayed healthcare during the lockdown was associated with a decrease in first-time dispensed analgesic drugs, especially among adolescents and adults. This may indicate untreated pain or increased reliance on over-the-counter alternatives during this period. SIGNIFICANCE STATEMENT: This Nationwide Dutch study showed a significant decline in first-time dispensed analgesic drugs during the first lockdown period of the COVID-19 pandemic, especially among adolescents and adults. This may indicate untreated pain due to delayed healthcare or an increased reliance on over-the-counter alternatives during this period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.